Super Vision Technology’s i-NYS Implantable Device Approved in China, Breaking the Treatment Barrier for Congenital Nystagmus
- Chris McMillan
- 1d
- 1 min read
Globe Newswire
16th March 2026
Super Vision Technology’s i-NYS Implantable Device Approved in China, Breaking the Treatment Barrier for Congenital Nystagmus
Super Vision
A groundbreaking advancement in ophthalmology has been achieved as Super Vision Technology announced that its i-NYS (Extraocular Neuromuscular Stimulator Implant), the world’s first implantable treatment device for congenital nystagmus, has received market approval from the National Medical Products Administration (NMPA). The device has been officially authorized for commercialization in China (Registration No.: 20263120535), marking a major milestone in addressing a condition long considered one of the most difficult to treat in ophthalmology.
Congenital Nystagmus: The "Incurable" Disease in OphthalmologyCongenital nystagmus (CN) involves involuntary, rhythmic, to-and-fro oscillations of the eyes. Patients often experience varying degrees of visual impairment, binocular visual dysfunction, and/or abnormal head position. It typically manifests between 3 - 6 months after birth and persists for life. With no significantly treatment available, congenital nystagmus has been regarded as an ‘incurable’ condition in ophthalmology.
Comments